Wolterk
Teleflex (New York Stock Exchange: TFX) reported a new investigation of real-world and controlled studies of the prostatic urethral lift (PUL) procedure with its UroLift system to treat men with benign prostatic hyperplasia (BPH).
The company said the results showed the benefits of early intervention with regarding the durability, improvement in symptoms and sexual function that urologists expect from the device to treat BPH, also called an enlarged prostate.
Data from more than 330 people with PUL studied in a controlled setting showed that, according to the company, PUL with UroLift lasted in most people between one and five years.
Teleflex added that the lower 1-year durability is related to undertreatment (≤4 implants placed). Lower 5-year durability is affected by poor baseline obstructive symptoms as indicated by the International Prostate Symptom Score (IPSS)
“These important new analyzes show that, whether compared to other interventions or medications, the UroLift system offers unique benefits that make it the treatment of choice for many men seeking long-term relief from bothersome BPH symptoms. “said Jacqueline Welch, vice president, global scientific and clinical operations, Teleflex.
The company presented the investigation at the 38thhe Annual Congress of the European Association of Urology (EAU) in Milan.
